Reviews of Physiology, Biochemistry and Pharmacology
- PDF / 2,648,695 Bytes
- 222 Pages / 437.04 x 666 pts Page_size
- 8 Downloads / 164 Views
Springer Berlin Heidelberg New York Hong Kong London Milan Paris' Tokyo
Reviews of
146 Physiology Biochemistryand Pharmacology Editors S.G. Amara, Portland • E. Bamberg, Frankfurt M.R Blaustein, Baltimore • H. Grunicke, Innsbruck R. Jahn, GOttingen • W.J. Lederer, Baltimore A. Miyajima, Tokyo • H. Murer, Z~rich S. Offermanns, Heidelberg ° N. Planner, Freiburg G. Schultz, Berlin • M. Schweiger, Berlin
With 21 Figures and 14 Tables
~ Springer
ISSN 0303-4240 ISBN 3-540-00228-6
Springer-Verlag
Berlin Heidelberg
New York
Library of Congress-Catalog-Card Number 74-3674 This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from SpringerVerlag. Violations are liable for prosecution under the German Copyright Law. Springer-Verlag Berlin Heidelberg New York a member of BertelsmannSpringer Science+Business Media GmbH http://www.springer.de © Springer-Verlag Berlin Heidelberg 2003 Printed in Germany The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. Product liability: The publishers cannot guarantee the accuracy of any information about dosage and application contained in this book. In every individual case the user must check such information by consulting the relevant literature. Printed on acid-free paper - 27/3150 or
5432 l 0
Rev Physiol Biochem Pharmacol (2003) 146:1–53 DOI 10.1007/s10254-002-0001-x
M. A. Jakupec · M. Galanski · B. K. Keppler
Tumour-inhibiting platinum complexes–state of the art and future perspectives
Published online: 4 February 2003 Springer-Verlag 2003
Abstract Thirty years after the onset of the first clinical studies with cisplatin, the development of antineoplastic platinum drugs continues to be a productive field of research. This article reviews the current preclinical and clinical status, including a discussion of the molecular basis for the activity of the parent drug cisplatin and platinum drugs of the second and third generation, in particular their interaction with DNA. Further emphasis is laid on the development of third generation platinum drugs with activity in cisplatin-resistant tumours, particularly on chelates containing 1,2-diaminocyclohexane (DACH) and on the promising and more recently evolving field of non-classic (trans- and multinuclear) platinum complexes. The development of oral platinum drugs and drug targeting strategies using liposomes, polymers or low-molecular-weight carriers in order to improve the
Data Loading...
